February 2017 Vol 10, No 1

The Dream of Value-Based Care
David B. Nash, MD, MBA
February 2017 Vol 10, No 1 - Editorial
Read More
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States
Joseph Lee, PhD, Ryan Pelkey, MS, Julieanna Gubitosa, BS, Michael F. Henrick, MBA, Michael L. Ganz, PhD
February 2017 Vol 10, No 1 - Business
Stakeholder Perspective
Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers
by Gary Branning, MBA
Read More
Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis
Kumar Mukherjee, PhD, Khalid M. Kamal, PhD
February 2017 Vol 10, No 1 - Business
Stakeholder Perspective
Understanding Patients’ Demographics Is Key to Improving Clinical and Economic Healthcare Outcomes
by F. Randy Vogenberg, PhD
Read More
Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD
Stanton R. Mehr
February 2017 Vol 10, No 1
Read More
Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends
Christopher B. Atzinger, MS, PhD candidate, Jeff J. Guo, BPharm, PhD
February 2017 Vol 10, No 1 - Business
Stakeholder Perspective
Rheumatoid Arthritis, Biologic Drugs, and Associated Cost
by Byron C. Scott, MD, MBA
Read More
Top 10 Healthcare Market Trends in 2017
John Santilli, MBA, F. Randy Vogenberg, PhD
February 2017 Vol 10, No 1 - Industry Trends
Read More

Results 1 - 6 of 6
  • Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME